CN1293906C - Chinese medicine preparation for treating rheumatism stagnation-syndrome pain - Google Patents
Chinese medicine preparation for treating rheumatism stagnation-syndrome pain Download PDFInfo
- Publication number
- CN1293906C CN1293906C CNB2004100110987A CN200410011098A CN1293906C CN 1293906 C CN1293906 C CN 1293906C CN B2004100110987 A CNB2004100110987 A CN B2004100110987A CN 200410011098 A CN200410011098 A CN 200410011098A CN 1293906 C CN1293906 C CN 1293906C
- Authority
- CN
- China
- Prior art keywords
- present
- chinese medicine
- parts
- starch
- dampness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 208000002193 Pain Diseases 0.000 title abstract description 25
- 208000011580 syndromic disease Diseases 0.000 title description 2
- 208000006820 Arthralgia Diseases 0.000 claims abstract description 23
- 241000908494 Dioscorea nipponica Species 0.000 claims abstract description 15
- 235000017008 Dioscorea nipponica Nutrition 0.000 claims abstract description 15
- 229920002472 Starch Polymers 0.000 claims abstract description 13
- 235000019698 starch Nutrition 0.000 claims abstract description 13
- 239000008107 starch Substances 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 4
- 239000000706 filtrate Substances 0.000 claims abstract description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 208000025747 Rheumatic disease Diseases 0.000 claims description 11
- 230000000552 rheumatic effect Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 238000009495 sugar coating Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 23
- 230000017531 blood circulation Effects 0.000 abstract description 8
- 230000006870 function Effects 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 241001528016 Ventilago Species 0.000 abstract 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 238000009501 film coating Methods 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 239000002574 poison Substances 0.000 abstract 1
- 231100000614 poison Toxicity 0.000 abstract 1
- 239000010409 thin film Substances 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 20
- 230000037396 body weight Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 201000003068 rheumatic fever Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 210000002105 tongue Anatomy 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 231100000862 numbness Toxicity 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 description 2
- 206010009866 Cold sweat Diseases 0.000 description 2
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- VNONINPVFQTJOC-ZGXDEBHDSA-N dioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O VNONINPVFQTJOC-ZGXDEBHDSA-N 0.000 description 2
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 240000008955 Dioscorea japonica Species 0.000 description 1
- 235000005251 Dioscorea japonica Nutrition 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 241000234272 Dioscoreaceae Species 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000800405 Spatholobus suberectus Species 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a traditional Chinese medicine for treating rheumatism, which belongs to the technical field of traditional Chinese medicines and particularly relates to a traditional Chinese medicine for dispelling wind and dampness, promoting blood circulation for removing obstruction in collaterals, eliminating coldness and relieving pain. The components of the medicine of the present invention have good treatment effect in the range of the following weight portions: 30 to 50 portions of smoothfruit ventilago roots and stems, 30 to 50 portions of dioscorea nipponica and 4 to 10 portions of starch. The preparation method of the present invention comprises the steps that the smoothfruit ventilago roots and stems and the dioscorea nipponica are added with water to be decocted twice; the time of the first decoction is 3 hours, and the time of the second decoction is 2 hours; solutions twice are respectively filtered, and filtrates are combined and concentrated into extract paste of 1.20 to 1.30 (at 25 DEG C) for standby; the starch is added into the extract paste to be uniformly mixed, and the present invention is prepared by granulation, drying, tablet forming and sugar or thin film coating. The present invention has the main functions of dispelling wind and dampness, promoting blood circulation for removing obstruction in collaterals, eliminating coldness and relieving pain, and is used for treating rheumatism. The present invention has exact treatment effect on treating rheumatism patients having rheumarthritis and wind-dampness-coldness arthralgia, has obvious treatment effect on treating rheumarthritis and wind-dampness-coldness arthralgia, and has the advantages of no poison side effect and adverse reactions in the period of medicine utilization.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to expelling wind and removing dampness, promoting blood circulation to remove obstruction in the collateral, dispersing cold for relieving pain Chinese medicine preparation, international Patent classificating number: A61K35/78, A61P29/00.
Background technology
Rheumatic arthritis and cold rheumatoid joint pain belong to the cold-damp arthromyodynia, are a kind of commonly encountered diseases, frequently-occurring disease, because human righteousness's deficiency, and exopathogen invasion and attack such as wind, cold, wet, heat, or interior living phlegm-damp, pyretic toxicity, congestion cause the passages through which vital energy circulates retardance, QI and blood is not smooth; Numbness person closes also, for bitterly meaning is closed not in resistance, and the pain that arthromyodynia is located with limbs, joint, muscle, muscles and bones etc., miserable, weight person's numbness, scorching hot, even arthroncus, joint stuffiness is so that be deformed into characteristics; The medicine of treatment rheumatic arthritis and cold rheumatoid joint pain is many now, for example: and pill for treating rheumatism and alleviating pain, rheumatic arthralgia cream, treating rheumatism disease pellet etc., but up to the present, still do not have the specific medicament of treatment rheumatic arthralgia.
Summary of the invention
The purpose of this invention is to provide a kind of a kind of Chinese medicine preparation for the treatment of rheumatic arthralgia with expelling wind and removing dampness, promoting blood circulation to remove obstruction in the collateral, dispersing cold for relieving pain function.
Each component of medicine of the present invention has better curative effect in the following weight parts scope:
Radix seu Caulis Verntilaginis Leiocarpae 30-50 part, Dioscorea nipponica bone 30-50 part, starch 4-10 part;
Be preferably: 35 parts of Radix seu Caulis Verntilaginis Leiocarpae, 35 parts in Dioscorea nipponica bone, 5 parts of starch;
The best is; 45 parts of Radix seu Caulis Verntilaginis Leiocarpae, 45 parts in Dioscorea nipponica bone, 6 parts of starch.
Preparation method of the present invention:
Get Radix seu Caulis Verntilaginis Leiocarpae, the Dioscorea nipponica bone decocts with water secondary, the 1st time 3 hours, the 2nd time 2 hours, gradation filtered, merging filtrate also is concentrated into the extractum of 1.20-1.30 (25 ℃), and is standby; Add starch, mixing is granulated, drying, and tabletting, sugar coating or film-coat promptly get the present invention.
Function of the present invention cures mainly: expelling wind and removing dampness, promoting blood circulation to remove obstruction in the collateral, dispersing cold for relieving pain are used for rheumatic arthralgia.
Usage and dosage of the present invention: oral, a 4-5 sheet, 3 times on the one.
Side of the present invention separates:
Radix seu Caulis Verntilaginis Leiocarpae is the dry rattan of leguminous plant spatholobus suberectus,
Meridian distribution of property and flavor: bitter, little sweet, warm, return Liver Channel;
Function: activating blood circulation, channels sootheing and network vessel quickening;
Cure mainly: menoxenia, blood deficiency and yellow complexion, paralysis and numbness, rheumatic arthralgia;
Composition: contain the pure and mild ferrum matter of Radix seu Caulis Verntilaginis Leiocarpae;
Pharmacology: promoting the circulation of blood is promoted blood circulation, warm waist knee joint, and the effect of bringing high blood pressure down is found in modern experiment; Isolated uterine there is inhibitory action, there is excitation in uterus on the throne, can strengthen the uterus rhythmicity and shrink; Total phosphorus metabolism in 24 hours has facilitation to Mouse Uterus.
Dioscorea nipponica bone another name dioscorea japonica, CHUANDILONG, Os Draconis, dragon grass, be Dioscoreaceae plant Dioscorea nipponica Mak. Ningpo Yam Rhizome rhizome;
Gather and process: spring, autumn excavate, and uproot and get stem, remove root hair, and crust (cork) dries;
Character: rhizome is cylindrical, class is cylindrical, and is crooked slightly, and the finger-like branch is arranged, different in size, diameter 0.3-1.5 centimetre, the surface is brown or yellow, both sides scattered palpus shape radicula or radicula mark of break, and matter is hard, and section is smooth, white or off-white color, mealiness, feeble QI, bitter and puckery flavor;
Chemical constituent: mainly contain dioscin multiple steroid saponins such as (dioscin);
Nature and flavor are warm in nature, sweet in the mouth, hardship;
Function cures mainly: relaxing muscles and tendons to promote blood circulation, cough-relieving pain relieving, wind-expelling pain-stopping cure mainly the ruined pain of waist, muscles and bones numbness, anemofrigid-damp arthralgia, traumatic injury, sprain one's back, cough and pant.
Pharmacodynamic test of active extract of the present invention:
One, test objective is observed antiinflammatory of the present invention, pain relieving and cold-resistant function by animal experiment.
Two, test material
1, medicine: the present invention, QUFENG ZHITONG JIAONANG (Xianyang Buchang Pharmaceutical Co., Ltd's production);
2, animal: Kunming kind white mice, body weight 18-25 gram, male and female dual-purpose; The Wistar rat, body weight 150-200 gram, male and female dual-purpose.White mice, the equal Shenyang Medical College of rat animal housing provide.
Three, test and result
1, the present invention is to the influence of 0.6% acetic acid induced mice writhing response
Get 50 of mices, male and female half and half, body weight 18-22 gram is divided into 5 groups at random by body weight, and water gastric infusion after 14 hours is can't help in fasting, and three dosage groups of the present invention are by 12.0 gram/kilograms, 8.0 gram/kilograms, 4.0 gram/kilograms (being equivalent to the crude drug amount) gastric infusion; Blank group is irritated the distilled water of capacity such as stomach, after the administration 45 minutes, inject 0.2 milliliter of 0.6% acetum for every mouse peritoneal, after 5 minutes in the record 10 minutes every mice body (abdominal part indent, stretch hind leg, buttocks is raised) number of times appears turning round.The results are shown in following table:
| Group | Dosage (gram/kilogram) | Number of animals (only) | Turn round the body number of times |
| The present invention | 12.0 | 10 | 18.2±5.9 * |
| The present invention | 8.0 | 10 | 20.1±4.6 |
| The present invention | 4.0 | 10 | 22.9±4.9 |
| QUFENG ZHITONG JIAONANG | 8.0 | 10 | 17.3±6.1 * |
| Blank | 10 | 26.8±7.2 |
The T check is compared with the blank group,
*P＜0.05.
2, the influence of xylol induced mice ear swelling of the present invention
Get 50 of mices, male and female half and half, body weight 20-25 gram is divided into 5 groups at random by body weight, 10 every group; Three dosage groups of the present invention are by 12.0 gram/kilograms, 8.0 gram/kilograms, 4.0 gram/kilograms (being equivalent to the crude drug amount) gastric infusion; QUFENG ZHITONG JIAONANG is by 8.0 gram/kilograms (being equivalent to the crude drug amount) gastric infusion, the distilled water of capacity such as blank group filling stomach, after the administration 45 minutes, with 5 seconds of dimethylbenzene cotton balls contact mice left side ear, draw neck to put to death animal after 15 minutes, with diameter 7mm card punch mice ears same area homalographic being downcut, is the swelling degree with left and right sides auricle weight difference, the results are shown in following table:
| Group | Dosage (gram/kilogram) | Number of animals (only) | Turn round the body number of times |
| The present invention | 12.0 | 10 | 6.45±1.36 ** |
| The present invention | 8.0 | 10 | 8.35±1.77 |
| The present invention | 4.0 | 10 | 7.52±1.68 * |
| QUFENG ZHITONG JIAONANG | 8.0 | 10 | 7.64±1.71 |
| Blank | 10 | 9.60±1.74 |
The T check is compared with the blank group,
*P＜0.05,
*P＜0.01.
3, cold-resistant function of the present invention
Get 50 of mices, male and female half and half, body weight 18-22 gram is divided into 5 groups at random by body weight; Three dosage groups of the present invention are irritated stomach by 12.0 gram/kilograms, 8.0 gram/kilograms, 4.0 gram/kilograms and are given aqueous suspension of the present invention; Positive controls is irritated stomach QUFENG ZHITONG JIAONANG aqueous suspension 8.0 gram/kilograms, the distilled water of capacity such as blank group filling stomach; After the administration 30 minutes, mice is put into-5 ± 1 ℃ of refrigerators, (one in a cage, refrigerator stays passage) took out after 2 hours, and statistics is respectively organized mice survival number, calculates and respectively organizes the mice survival rate, the results are shown in following table:
| Group | Number of animals (only) | Dosage (gram/kilogram) | The survival number of elements | Survival rate (%) |
| Blank | 10 | 3 | 30 | |
| The present invention | 10 | 12 | 8 Δ | 80 |
| The present invention | 10 | 8 | 6 | 60 |
| The present invention | 10 | 4 | 4 | 40 |
| QUFENG ZHITONG JIAONANG | 10 | 8 | 6 | 60 |
The T check is compared Δ＜0.05 with the blank group.
Conclusion: the present invention can suppress the mice ear due to the dimethylbenzene; That reduces by 0.6% acetic acid induced mice turns round the body number of times; Improve the tolerance to cold of mice.Illustrate that the present invention has certain antiinflammatory, pain relieving and cold-resistant function.
Acute toxicity test of the present invention:
Test method is got fasting and be can't help 20 of 12 hours healthy mices of water, male and female half and half, and body weight 18-22 gram is irritated stomach respectively and is given aqueous suspension of the present invention (0.35 grams per milliliter is equivalent to the crude drug amount) 0.4 milliliter/10 grams, and one day twice, 6 hours at interval; Observe 1 every day after the administration, observed continuously 7 days; Movable minimizing on the same day after the mice administration as a result, indivedual mice lassitudes recovered normal in second day, and the mice general state is good in 7 days, and body weight gain is normal, none death.
The result: it is 28.0 gram/kilograms (suitable crude drug amounts) that the present invention gives the maximum tolerated dose of mouse stomach administration, is 133.3 times of the clinical daily dose of being grown up.
Long term toxicity test of the present invention:
Test method is got 80 of the healthy istar rat of W in normal one week of raising, measure routine blood test and biochemical indicator, be divided into 4 groups at random by body weight, every group 20, male and female half and half, large, medium and small three the dosage groups of the present invention are respectively by 8.0 gram/kilograms, 6.0 gram/kilograms, 4.0 gram/kilograms (quite crude drug amount) gastric infusion, the distilled water of capacity such as blank group filling stomach, be administered once every day, 12 weeks of successive administration, per 4 weeks are surveyed a body weight, general state, behavioral activity, diet drinking-water, defecation and other poisoning manifestations of observing a rat every day; After the last administration 24 hours, routine blood test and biochemical indicator were measured in blood sampling, sacrifice of animal 50%, dissect core, liver, spleen, stomach, kidney main organs weigh, and do histopathologic examination; Remaining 50% animal is put to death after normally raising for 2 weeks, carries out above-mentioned inspection equally, the recovery situation after the observation drug withdrawal.
Rat continuous irrigation stomach gives the present invention's 8.0 gram/kilograms, 6.0 gram/kilograms, 4.0 gram/kilograms (quite crude drug amount) as a result, be administered once every day, 12 weeks of successive administration, be respectively adult 38.1,28.6 and 19.0 times of a clinical daily dose, rat growth as a result is normal, routine blood test and biochemical investigation no abnormality seen change, and main organs coefficient and histological examination there is no toxic pathology and change; Illustrate that the clinical using dosage of the present invention is safe and reliable, maximal non-toxic effect dosage is 8.0 gram/kilograms.
Clinical trial of the present invention:
This group of physical data case 400 examples are divided into test group 300 examples at random, matched group 100 examples;
| Age | The state of an illness | The course of disease | The symptom scores accumulated | |||||||||
| Maximum | Minimum | On average | Slight person | Moderate person | Severe person | The shortest | The longest | On average | Minimum | At most | On average | |
| Experimental group 300 examples | 65 | 18 | 3915± 10.74 | 75 | 179 | 46 | 3 months | 6 years | 2.19 ±1.38 | 9 | 26 | 14.39 ±3.79 |
| Matched group 100 examples | 64 | 18 | 39.13 ±11.37 | 30 | 60 | 10 | 3 months | 5 years | 2.04 ±1.33 | 8 | 25 | 14.27 ±4.15 |
Diagnostic criteria is according to the unified combination of Chinese and Western medicine diagnostic criteria of " rheumatism tremble with fear sick academic forum " specified " rheumatic four diseases " in 1985 and specified standard of standard of in April, 1988 whole nation combination of Chinese and Western medicine rheumatism academic conference revision.
Traditional Chinese medical science typing standard
Syndrome of cold-dampness blocking collaterals: the limbs joint cold type of pain is heavy, or swelling, and local fear of cold, color of the leather are not red, and that touches is not hot, meets the cold pain that increases, hotly then subtract, enlarged tongue, matter is light dark, tongue is greasy in vain or sliding white, stringy and tense pulse or string are slow.
Mild symptoms weight classification and integration method
| Symptom | Heavy (3 minutes) | In (2 minutes) | Gently (1 minute) | Do not have (0 minute) |
| *Arthralgia | Severe pain is difficult because of bearing | Pain still can be stood | Pain slightly | No pain |
| *Limbs are heavy | Heavy obvious, influence activity | Heavyly obviously influence activity slightly | The heavy activity that do not influence is arranged slightly | No sense of heaviness |
| Local cool | Obviously there is cool sense the part, very then is in a cold sweat | There are cool sense, no cold sweat in the part | The part has cool sense slightly | There is not cool sense |
| Swelling | Swelling is obvious | Swelling | Swelling slightly | No swelling |
| Local fear of cold | Local fear of cold is obvious | Local fear of cold | Local milli fear of cold | No fear of cold |
| Meet the cold pain that increases | Meeting cold pain obviously increases | Meeting cold pain increases | Meeting cold pain increases slightly | Meeting cold pain does not increase |
| Picture of the tongue | (counting 1 fen) arranged | Do not have (counting 0 fen) | ||
| Pulse condition | (counting 1 fen) arranged | Do not have (counting 0 fen) | ||
Annotate: 1.
*On former score basis superior 2; 2. state of an illness severe 〉=19 minute, moderate 11-18, slight≤10 minutes.
Clinical indexes:
One, safety detects index
1, general health check-up project; 2, blood, urine, just routine examination; 3, the heart, liver, kidney function test.
Two, health giving quality observation index
1, observe muscle arthralgia, heavy, swelling, there are cool sense or fear of cold in the part, meets the cold situation of change that increases symptom such as pain and tongue, arteries and veins treatment front and back;
2, erythrocyte sedimentation rate, anti-chain physics and chemistry such as " O " detect the situation of change of index treatment front and back.
Observe and administrated method
To meet the rheumatic arthritis and cold rheumatoid joint pain patient 400 examples of diagnostic criteria, be divided into test group 300 examples, matched group 100 examples; Test group is taken the present invention's (every contains crude drug 1.00 grams), and is every day 3 times, each 5, oral; Matched group is taken the FENGSHI GUANJIEYAN PIAN that Baicheng Wanda pharmaceutcal corporation, Ltd produces, and every day 2 times, each 4, oral, one month is a course of treatment, all observes a course of treatment, and stopping using the observation period, other has the medicine of associated treatment effect.
Curative effect determinate standard
1, clinic control; Clinical symptoms all disappears, and it is normal that the tongue arteries and veins recovers, and integration is zero;
2, produce effects: clinical symptoms obviously disappears, and the treatment back preceding integration of treatment descends 〉=2/3;
3, effective: clinical symptom relief, integration descended＜2/3, 〉=1/3 before treated the treatment back;
4, invalid: clinical symptoms does not have obvious improvement, and the treatment back preceding integration of treatment descends＜1/3.
Test group and matched group general curative effect are relatively
| Group | The example number | Clinic control | Produce effects | Effectively | Invalid | Show control rate % | Total effective rate % |
| Example (%) | Example (%) | Example (%) | Example (%) | ||||
| Test group | 300 | 47(15.67) | 123(41) | 98(32.67) | 32(10.67) | 56.67 | 89.33 |
| Matched group | 100 | 13(13) | 26(26) | 38(38) | 23(23) | 39 | 77 |
U＝2.98 P＜0.01
Last table is analyzed through Ridit, U=2.98, and there is significant difference P＜0.01, and prompting investigational agent curative effect obviously is better than matched group.
The different sick curative effects of planting of test group compare
| The sick kind | The example number | Clinic control | Produce effects | Effectively | Invalid | Show control rate % | Total effective rate % |
| Example (%) | Example (%) | Example (%) | Example (%) | ||||
| Arthritis | 56 | 6(10.71) | 15(26.79) | 22(39.29) | 13(23.21) | 37.5 | 76.79 |
| Arthralgia | 244 | 41(16.80) | 108(44.26) | 76(31.15) | 19(7.79) | 61.06 | 92.21 |
U＝2.98 P＜0.01
Last table is analyzed through Ridit, U=2.98, and there is significant difference P＜0.01, and the prompting investigational agent is better than rheumatic arthritis to the curative effect of cold rheumatoid joint pain.
In sum, the present invention treats rheumatic arthritis and cold rheumatoid joint pain belongs to cold-damp arthromyodynia person determined curative effect, still is that cold rheumatoid joint pain all has obvious curative effects to rheumatic arthritis no matter, and the curative effect of cold rheumatoid joint pain is better than rheumatic arthritis; Patient to different sexes, all ages and classes section, the different state of an illness and the different courses of disease all is suitable for, and does not find toxic and side effects and untoward reaction during medication; Determined curative effect of the present invention, safety in utilization.
The specific embodiment
Embodiment 1:
It is standby to get 35 parts of Radix seu Caulis Verntilaginis Leiocarpae, 35 parts in Dioscorea nipponica bone, 5 parts of starch;
Preparation method of the present invention:
Get Radix seu Caulis Verntilaginis Leiocarpae, the Dioscorea nipponica bone decocts with water secondary, the 1st time 3 hours, the 2nd time 2 hours, gradation filtered, merging filtrate also is concentrated into the extractum of 1.20-1.30 (25 ℃), and is standby; Add starch, mixing is granulated, drying, and tabletting, sugar coating or film-coat promptly get the present invention.
Embodiment 2:
It is standby to get 45 parts of Radix seu Caulis Verntilaginis Leiocarpae, 45 parts in Dioscorea nipponica bone, 6 parts of starch;
Preparation method is with embodiment 1.
Claims (4)
1, a kind of Chinese medicine preparation for the treatment of rheumatic arthralgia, make by the following weight parts crude drug:
Radix seu Caulis Verntilaginis Leiocarpae 30-50 part, Dioscorea nipponica bone 30-50 part, starch 4-10 part.
2, a kind of Chinese medicine preparation for the treatment of rheumatic arthralgia according to claim 1, wherein the consumption of each crude drug is: 35 parts of Radix seu Caulis Verntilaginis Leiocarpae, 35 parts in Dioscorea nipponica bone, 5 parts of starch.
3, a kind of Chinese medicine preparation for the treatment of rheumatic arthralgia according to claim 1, wherein the consumption of each crude drug is: 45 parts of Radix seu Caulis Verntilaginis Leiocarpae, 45 parts in Dioscorea nipponica bone, 6 parts of starch.
4, the method for the Chinese medicine preparation of the described treatment rheumatic arthralgia of preparation claim 1:
Get Radix seu Caulis Verntilaginis Leiocarpae, the Dioscorea nipponica bone decocts with water secondary, the 1st time 3 hours, the 2nd time 2 hours, gradation filtered, and is at 25 ℃ of merging filtrates and be concentrated into the extractum of 1.20-1.30, standby; Add starch, mixing is granulated drying, tabletting, sugar coating or film-coat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100110987A CN1293906C (en) | 2004-09-17 | 2004-09-17 | Chinese medicine preparation for treating rheumatism stagnation-syndrome pain |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100110987A CN1293906C (en) | 2004-09-17 | 2004-09-17 | Chinese medicine preparation for treating rheumatism stagnation-syndrome pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1748763A CN1748763A (en) | 2006-03-22 |
| CN1293906C true CN1293906C (en) | 2007-01-10 |
Family
ID=36604540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100110987A Expired - Lifetime CN1293906C (en) | 2004-09-17 | 2004-09-17 | Chinese medicine preparation for treating rheumatism stagnation-syndrome pain |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1293906C (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1073870A (en) * | 1992-10-26 | 1993-07-07 | 常民 | The preparation method of neck-building medicine |
| CN1490017A (en) * | 2002-10-14 | 2004-04-21 | 何廷银 | Medicines against rheunatoid and rheumatic diseases |
-
2004
- 2004-09-17 CN CNB2004100110987A patent/CN1293906C/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1073870A (en) * | 1992-10-26 | 1993-07-07 | 常民 | The preparation method of neck-building medicine |
| CN1490017A (en) * | 2002-10-14 | 2004-04-21 | 何廷银 | Medicines against rheunatoid and rheumatic diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1748763A (en) | 2006-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103463539B (en) | A kind of medicine for the treatment of eczema and its production and use | |
| CN100358549C (en) | Diarrhea treating chinese medicine composition | |
| CN103120719A (en) | Pure traditional Chinese medicine composition for treating sacbrood virus of bees and preparation method thereof | |
| CN103705796B (en) | A kind of pharmaceutical composition for the treatment of diarrhoea and preparation method thereof | |
| CN1709302A (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
| CN104524247B (en) | One treats migrainous medical composition and its use | |
| CN100548363C (en) | Medicine of treatment benign prostate hyperplasia and preparation method thereof | |
| CN104706953A (en) | Traditional Chinese medicine preparation for treating chronic cervicitis | |
| CN1197614C (en) | Chinese medicine cap sule for treating prostatic disorders | |
| CN1293906C (en) | Chinese medicine preparation for treating rheumatism stagnation-syndrome pain | |
| CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN103860894B (en) | A kind of medicine for the treatment of chronic prostatitis | |
| CN104622995A (en) | Pharmaceutical composition for treating chronic superficial gastritis and preparation method of pharmaceutical composition | |
| CN1943701B (en) | A kind of medicine for treatment of non-gonococcal urethritis(NGU) and its preparation method | |
| CN1301125C (en) | Medicine for treating gastrointestinal tract disease | |
| CN1209162C (en) | Medicinal composition for treating acne and chloasma | |
| CN1186052C (en) | Medicine for treatment of pelvic inflammation, its preparation and preparing method | |
| CN106943554A (en) | A kind of Chinese medicine composition for being used to treat chordapsus | |
| CN1284588C (en) | Medicine for treating gastrointestinal tract diseases | |
| CN1951464A (en) | Compound Chinese medicinal preparation for treating gynecological inflammation and preparation method thereof | |
| CN1313142C (en) | Pharmaceutical composition with exterior syndrome easing, cough and asthma easing function | |
| CN104958530A (en) | Traditional Chinese medicinal composition for treating infantile pneumonia | |
| CN1751596A (en) | Health-care food and its soft capsule for improving immunity of anti alimentary canal infection, and its prepn. method | |
| CN102552706B (en) | Medicine for treating vascular dementia and preparation method thereof | |
| CN116726083A (en) | Traditional Chinese medicine composition for treating chronic prostatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: XIUZHENG PHARMACEUTICAL GROUP BEIJING XIUZHENG PHARMACEUTICAL CO.,LTD. Assignor: Xiu Laigui Contract fulfillment period: 2008.6.28 to 2018.6.27 Contract record no.: 2009110000066 Denomination of invention: Chinese medicine preparation for treating rheumatism stagnation-syndrome pain Granted publication date: 20070110 License type: Exclusive license Record date: 20090505 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.6.28 TO 2018.6.27; CHANGE OF CONTRACT Name of requester: XIUZHENG PHARMACEUTICAL INDUSTRY GROUP BEIJING XIU Effective date: 20090505 |
|
| ASS | Succession or assignment of patent right |
Owner name: TONGYAO PHARMACEUTICAL GROUP STOCK CO., LTD. Free format text: FORMER OWNER: XIU LAIGUI Effective date: 20150525 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 130012 CHANGCHUN, JILIN PROVINCE TO: 134000 TONGHUA, JILIN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150525 Address after: 134000 amendment Road 39, Jilin, Tonghua Patentee after: Tongyao Pharmaceutical Group Corp. Address before: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin, China Patentee before: Xiu Laigui |
|
| CX01 | Expiry of patent term |
Granted publication date: 20070110 |